When discussing arthritis, it is commonly associated with older adult populations, but a notable number of pediatric patients are also affected by the condition. The Centers for Disease Control and Prevention estimated that around 220,000 children in the United States experienced the condition between 2017 and 2021.
Given the substantial burden of juvenile arthritis, including the condition’s potential to cause long-term damage and psychosocial impacts on a pediatric patient's mental health, there is a critical need for effective treatment strategies. As a result there are numerous ongoing clinical trials for juvenile arthritis with the overall objective of improving patient outcomes.
Today we’re spotlighting five of the most recent clinical trials focusing on juvenile arthritis.
| Study Title | Phase | Enrollment | Start Date | Completion Date |
|---|---|---|---|---|
| An Extension Study of Subcutaneous Secukinumab in Patients with Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA) | 3 | 55 | June 2019 | November 2024 |
| Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA) | 3 | 121 | October 2019 | January 2025 |
| Long-term Safety Study of Tofacitinib in Patients with Juvenile Idiopathis Arthritis | 3 | 302 | March 2013 | February 2025 |
| Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis. (SELECT-sJIA) | 3 | 90 | October 2023 | June 2029 (estimated) |
| A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants with Juvenile Psoriatic Arthritis | 3 | 60 | March 2025 | March 2030 (estimated) |
Phase 3 Clinical Trials
An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)
- Sponsor: Novartis Pharmaceuticals
- Goal: Investigate the efficacy and safety of secukinumab treatment in Juvenile Idiopathic Arthritis (JIA) subtypes of Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA).
- Interventions: Secukinumab
- Primary Outcome Measure: Percentage of Participants With Juvenile Idiopathic Arthritis American College of Rheumatology (JIA ACR) 30 Response.
- Study Details
- Source
Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA)
- Sponsor: Duke University
- Goal: Evaluate the effectiveness of a 24-week course of treatment with abatacept plus usual care versus usual care to prevent polyarthritis (≥5 joints), uveitis, or treatment with other systemic medication within 18 months of randomization in children with recent-onset limited JIA.
- Interventions: Abatacept Injection, Usual care
- Primary Outcome Measures: Change in joint count by physician exam parts 1 and 2; Change in number of participants with active anterior uveitis parts 1 and 2.
- Study Details
- Source
Long-Term Safety Study of Tofacitinib in Patients with Juvenile Idiopathic Arthritis
- Sponsor: Pfizer
- Goal: Evaluate long-term safety and tolerability of tofacitinib in patients with JIA, who have previously participated in tofacitinib JIA studies.
- Interventions: Tofacitinib
- Primary Outcome Measure: Standard laboratory safety data and adverse event (AE) reports. Body weight, height and Tanner Stages will collected to assess growth and physical development.
- Study Details
- Source
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis. (SELECT-sJIA)
- Sponsor: AbbVie
- Goal: Assess how safe and effective upadacitinib is in treating pediatric and adolescent participants aged 1 to < 18 with systemic juvenile idiopathic arthritis (sJIA) and will include a tocilizumab treatment arm for reference. Adverse events and change in the disease activity will be assessed.
- Interventions: Upadacitinib, Tocilizumab
- Primary Outcome Measures: Percentage of Participants Achieving Adapted systemic Juvenile Idiopathic Arthritis (sJIA) American College of Rheumatology (ACR) 30 Response; Number of Participants with Adverse Events (AEs).
- Study Details
- Source
A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants with Juvenile Psoriatic Arthritis
- Sponsor: Bristol-Myers Squibb
- Goal: Evaluate the drug levels, efficacy, and safety of Deucravacitinib (BMS-986165) in pediatric participants with juvenile psoriatic arthritis.
- Interventions: Deucravacitinib, placebo
- Primary Outcome Measure: Time to first flare during the withdrawal period.
- Study Details
- Source
Related Guidelines Include:
- Management of Juvenile Idiopathic Arthritis
- Australian Rheumatology Association
- Latest Update: July 2023
- Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis
- American College of Rheumatology
- Latest Update: April 2022
- Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging
- American College of Rheumatology
- Latest Update: April 2022
- Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis
- American College of Rheumatology
- Latest Update: April 2019
- Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis
- American College of Rheumatology
- Latest Update: April 2019
Sign up for alerts and stay informed on the latest clinical trials and their impact on related guidelines.
Copyright © 2025 Guideline Central, all rights reserved.